Literature DB >> 23786352

Characterization of joint disease in mucopolysaccharidosis type I mice.

Patricia G de Oliveira1, Guilherme Baldo, Fabiana Q Mayer, Barbara Martinelli, Luise Meurer, Roberto Giugliani, Ursula Matte, Ricardo M Xavier.   

Abstract

Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by mutations in enzymes that degrade glycosaminoglycans (GAGs). Joint disease is present in most forms of MPS, including MPS I. This work aimed to describe the joint disease progression in the murine model of MPS I. Normal (wild-type) and MPS I mice were sacrificed at different time points (from 2 to 12 months). The knee joints were collected, and haematoxylin-eosin staining was used to evaluate the articular architecture. Safranin-O and Sirius Red staining was used to analyse the proteoglycan and collagen content. Additionally, we analysed the expression of the matrix-degrading metalloproteinases (MMPs), MMP-2 and MMP-9, using immunohistochemistry. We observed progressive joint alterations from 6 months, including the presence of synovial inflammatory infiltrate, the destruction and thickening of the cartilage extracellular matrix, as well as proteoglycan and collagen depletion. Furthermore, we observed an increase in the expression of MMP-2 and MMP-9, which could conceivably explain the degenerative changes. Our results suggest that the joint disease in MPS I mice may be caused by a degenerative process due to increase in proteases expression, leading to loss of collagen and proteoglycans. These results may guide the development of ancillary therapies for joint disease in MPS I.
© 2013 The Authors. International Journal of Experimental Pathology © 2013 International Journal of Experimental Pathology.

Entities:  

Keywords:  alpha-L-iduronidase; joint disease; matrix metalloproteinases; mucopolysaccharidoses type I

Mesh:

Substances:

Year:  2013        PMID: 23786352      PMCID: PMC3781776          DOI: 10.1111/iep.12033

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  19 in total

1.  Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly.

Authors:  A Hinek; S E Wilson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  Matrix metalloproteinase degradation of extracellular matrix: biological consequences.

Authors:  S D Shapiro
Journal:  Curr Opin Cell Biol       Date:  1998-10       Impact factor: 8.382

Review 3.  Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I).

Authors:  Gregory M Pastores; Patrick A Meere
Journal:  Curr Opin Rheumatol       Date:  2005-01       Impact factor: 5.006

4.  Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models.

Authors:  Calogera M Simonaro; Marina D'Angelo; Mark E Haskins; Edward H Schuchman
Journal:  Pediatr Res       Date:  2005-03-03       Impact factor: 3.756

5.  A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis.

Authors:  Dianna C Martin; Vasantha Atmuri; Richard J Hemming; Judith Farley; John S Mort; Sharon Byers; Sabine Hombach-Klonisch; Antonei B Csoka; Robert Stern; Barbara L Triggs-Raine
Journal:  Hum Mol Genet       Date:  2008-03-15       Impact factor: 6.150

6.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

7.  Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.

Authors:  Xiucui Ma; Mindy Tittiger; Russell H Knutsen; Attila Kovacs; Laura Schaller; Robert P Mecham; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-05-13       Impact factor: 4.797

8.  Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.

Authors:  L A Clarke; C S Russell; S Pownall; C L Warrington; A Borowski; J E Dimmick; J Toone; F R Jirik
Journal:  Hum Mol Genet       Date:  1997-04       Impact factor: 6.150

9.  Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.

Authors:  Guilherme Baldo; Fabiana Quoos Mayer; Barbara Martinelli; Anna Dilda; Fabiola Meyer; Katherine P Ponder; Roberto Giugliani; Ursula Matte
Journal:  Behav Brain Res       Date:  2012-05-09       Impact factor: 3.332

10.  Murine MPS I: insights into the pathogenesis of Hurler syndrome.

Authors:  C Russell; G Hendson; G Jevon; T Matlock; J Yu; M Aklujkar; K Y Ng; L A Clarke
Journal:  Clin Genet       Date:  1998-05       Impact factor: 4.438

View more
  7 in total

1.  Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.

Authors:  Roselena Silvestri Schuh; Esteban Alberto Gonzalez; Angela Maria Vicente Tavares; Bruna Gazzi Seolin; Lais de Souza Elias; Luisa Natalia Pimentel Vera; Francyne Kubaski; Edina Poletto; Roberto Giugliani; Helder Ferreira Teixeira; Ursula Matte; Guilherme Baldo
Journal:  Gene Ther       Date:  2019-12-11       Impact factor: 5.250

2.  Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.

Authors:  Yian Khai Lau; Sun H Peck; Toren Arginteanu; Meilun Wu; Megan Lin; Eileen M Shore; Peter S Klein; Margret L Casal; Lachlan J Smith
Journal:  Bone       Date:  2021-10-22       Impact factor: 4.398

3.  The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.

Authors:  Gabriele Giacomo Schiattarella; Giuliana Cerulo; Valeria De Pasquale; Pasquale Cocchiaro; Orlando Paciello; Luigi Avallone; Maria Paola Belfiore; Francesca Iacobellis; Daniele Di Napoli; Fabio Magliulo; Cinzia Perrino; Bruno Trimarco; Giovanni Esposito; Paola Di Natale; Luigi Michele Pavone
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

4.  Characterization of the MPS I-H knock-in mouse reveals increased femoral biomechanical integrity with compromised material strength and altered bone geometry.

Authors:  Arin K Oestreich; Mekka R Garcia; Xiaomei Yao; Ferris M Pfeiffer; Sabah Nobakhti; Sandra J Shefelbine; Yong Wang; Amanda C Brodeur; Charlotte L Phillips
Journal:  Mol Genet Metab Rep       Date:  2015-09-07

Review 5.  Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.

Authors:  Valeria De Pasquale; Anna Moles; Luigi Michele Pavone
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

6.  Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I.

Authors:  Troy C Lund; Terence M Doherty; Julie B Eisengart; Rebecca L Freese; Kyle D Rudser; Ellen B Fung; Bradley S Miller; Klane K White; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  JIMD Rep       Date:  2020-12-08

7.  Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II.

Authors:  Lynda E Polgreen; Alicia Kunin-Batson; Kyle Rudser; Richard K Vehe; Jeanine J Utz; Chester B Whitley; Patricia Dickson
Journal:  Mol Genet Metab Rep       Date:  2017-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.